Viridian Therapeutics, Inc. (VRDN) — Analyst outlook / Analyst consensus target is. Based on 16 analyst ratings, the consensus is bullish — 13 Buy, 3 Hold.
The consensus price target is $43.10 (low: $34.00, high: $50.00), representing an upside of 183.7% from the current price $15.19.
Analysts estimate Earnings Per Share (EPS) of $-4.00 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.98 vs est $-4.00 (beat +0.5%). 2025: actual $-3.32 vs est $-3.53 (beat +6%). Analyst accuracy: 97%.
VRDN Stock — 12-Month Price Forecast
$43.10
▲ +183.74% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Viridian Therapeutics, Inc., the average price target is $43.10, with a high forecast of $50.00, and a low forecast of $34.00.
The average price target represents a +183.74% change from the last price of $15.19.
Highest Price Target
$50.00
Average Price Target
$43.10
Lowest Price Target
$34.00
VRDN Analyst Ratings
Buy
Based on 16 analysts giving stock ratings to Viridian Therapeutics, Inc. in the past 3 months
EPS Estimates — VRDN
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.98
vs Est –$4.00
▲ 0.5% off
2025
Actual –$3.32
vs Est –$3.53
▲ 6.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — VRDN
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▼ 5.1% off
2025
Actual $0.071B
vs Est $0.085B
▼ 20.6% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
